Evaxion A (EVAX) Net Margin (2024 - 2025)
Evaxion A's (EVAX) quarterly Net Margin came in at 61.64% in Q3 2025, up 12578.0% YoY from N/an in Q3 2024, and up 100.47% on a QoQ basis from 13056.76% in Q2 2025.
Evaxion A (EVAX) Net Margin (2024 - 2025) Analysis & Trends
Evaxion A (EVAX) has 2 years of Net Margin data on file, last reported at 61.64% in Q3 2025.
- Quarterly Net Margin rose 12578.0% year-over-year to 61.64% in Q3 2025, while the trailing twelve-month figure through Mar 2026 was 129.63% (up 27553.0% YoY) and the FY2025 annual result came in at 102.38%, up 21362.0% from the prior year.
- Net Margin improved to 61.64% in Q3 2025, from 13056.76% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 2341.18% in Q1 2024 to a low of 13056.76% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 12.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -3.12% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.51% |
| 10 | Evaxion A | 26.86 Mn | 26.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 61.64% |
| Jun 30, 2025 | -13,056.76% |
| Dec 31, 2024 | -2,974.59% |
| Sep 30, 2024 | -64.14% |
| Jun 30, 2024 | -4,024.68% |
| Mar 31, 2024 | 2,341.18% |